You can seek FDA approval to launch a generic drug before the expiration of ACTONEL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ACTONEL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ACTONEL:-

You can seek FDA approval to launch a generic drug before the expiration of AGGRASTAT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AGGRASTAT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AGGRASTAT:-

You can seek FDA approval to launch a generic drug before the expiration of BANZEL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BANZEL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BANZEL:-

You can seek FDA approval to launch a generic drug before the expiration of BONIVA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BONIVA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BONIVA:-

You can seek FDA approval to launch a generic drug before the expiration of EXFORGE HCT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EXFORGE HCT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EXFORGE HCT:-

You can seek FDA approval to launch a generic drug before the expiration of MYDAYIS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MYDAYIS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MYDAYIS:-

You can seek FDA approval to launch a generic drug before the expiration of NAROPIN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NAROPIN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NAROPIN:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of POMALYST's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the POMALYST's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on POMALYST:-

You can seek FDA approval to launch a generic drug before the expiration of PROMACTA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PROMACTA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PROMACTA:-

You can seek FDA approval to launch a generic drug before the expiration of PROMACTA KIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PROMACTA KIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PROMACTA KIT:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of REVLIMID's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the REVLIMID's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on REVLIMID:-

You can seek FDA approval to launch a generic drug before the expiration of SELZENTRY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SELZENTRY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SELZENTRY:-

You can seek FDA approval to launch a generic drug before the expiration of STENDRA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the STENDRA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on STENDRA:-